NASDAQ:IRIX

IRIDEX Competitors

$7.71
+0.23 (+3.07 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.36
Now: $7.71
$7.79
50-Day Range
$5.88
MA: $7.07
$7.71
52-Week Range
$1.46
Now: $7.71
$8.28
Volume141,183 shs
Average Volume382,587 shs
Market Capitalization$119.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

IRIDEX (NASDAQ:IRIX) Vs. EDAP, EYES, BSGM, FONR, SLNO, and NDRA

Should you be buying IRIX stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to IRIDEX, including Edap Tms (EDAP), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), FONAR (FONR), Soleno Therapeutics (SLNO), and ENDRA Life Sciences (NDRA).

IRIDEX (NASDAQ:IRIX) and Edap Tms (NASDAQ:EDAP) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

IRIDEX has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.

Profitability

This table compares IRIDEX and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IRIDEX-21.54%-38.60%-24.99%
Edap Tms-4.03%-11.54%-5.78%

Analyst Ratings

This is a breakdown of current ratings and price targets for IRIDEX and Edap Tms, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IRIDEX00203.00
Edap Tms00303.00

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' higher probable upside, analysts clearly believe Edap Tms is more favorable than IRIDEX.

Earnings and Valuation

This table compares IRIDEX and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

32.6% of IRIDEX shares are owned by institutional investors. 2.0% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Edap Tms beats IRIDEX on 10 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Earnings & Valuation

This table compares Second Sight Medical Products and IRIDEX's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05

IRIDEX has higher revenue and earnings than Second Sight Medical Products. IRIDEX is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Second Sight Medical Products and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
IRIDEX-21.54%-38.60%-24.99%

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 67.5% of Second Sight Medical Products shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Second Sight Medical Products and IRIDEX, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
IRIDEX00203.00

IRIDEX has a consensus price target of $6.50, indicating a potential downside of 15.69%. Given IRIDEX's higher probable upside, analysts clearly believe IRIDEX is more favorable than Second Sight Medical Products.

Summary

IRIDEX beats Second Sight Medical Products on 8 of the 13 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and BioSig Technologies (NASDAQ:BSGM) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

IRIDEX has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.

Earnings and Valuation

This table compares IRIDEX and BioSig Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A

IRIDEX has higher revenue and earnings than BioSig Technologies.

Profitability

This table compares IRIDEX and BioSig Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IRIDEX-21.54%-38.60%-24.99%
BioSig TechnologiesN/A-244.64%-213.88%

Institutional & Insider Ownership

32.6% of IRIDEX shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 2.0% of IRIDEX shares are held by company insiders. Comparatively, 19.5% of BioSig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IRIDEX and BioSig Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IRIDEX00203.00
BioSig Technologies0000N/A

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Given IRIDEX's higher possible upside, equities analysts clearly believe IRIDEX is more favorable than BioSig Technologies.

Summary

IRIDEX beats BioSig Technologies on 7 of the 10 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and FONAR (NASDAQ:FONR) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

IRIDEX has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IRIDEX and FONAR, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IRIDEX00203.00
FONAR0000N/A

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Given IRIDEX's higher possible upside, equities analysts clearly believe IRIDEX is more favorable than FONAR.

Earnings and Valuation

This table compares IRIDEX and FONAR's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05
FONAR$85.69 million1.40$8.24 millionN/AN/A

FONAR has higher revenue and earnings than IRIDEX.

Profitability

This table compares IRIDEX and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IRIDEX-21.54%-38.60%-24.99%
FONAR8.28%5.57%3.99%

Institutional & Insider Ownership

32.6% of IRIDEX shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 2.0% of IRIDEX shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

FONAR beats IRIDEX on 8 of the 12 factors compared between the two stocks.

Soleno Therapeutics (NASDAQ:SLNO) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Valuation and Earnings

This table compares Soleno Therapeutics and IRIDEX's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05

IRIDEX has higher revenue and earnings than Soleno Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Soleno Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Soleno Therapeutics and IRIDEX, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soleno Therapeutics00303.00
IRIDEX00203.00

Soleno Therapeutics presently has a consensus target price of $8.6667, indicating a potential upside of 653.62%. IRIDEX has a consensus target price of $6.50, indicating a potential downside of 15.69%. Given Soleno Therapeutics' higher possible upside, equities research analysts plainly believe Soleno Therapeutics is more favorable than IRIDEX.

Institutional and Insider Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of IRIDEX shares are owned by institutional investors. 74.9% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 2.0% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Soleno Therapeutics and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soleno TherapeuticsN/A-88.69%-51.63%
IRIDEX-21.54%-38.60%-24.99%

IRIDEX (NASDAQ:IRIX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Valuation and Earnings

This table compares IRIDEX and ENDRA Life Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05
ENDRA Life Sciences$10,000.009,068.80$-13,310,000.00($2.34)-0.93

IRIDEX has higher revenue and earnings than ENDRA Life Sciences. IRIDEX is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IRIDEX has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for IRIDEX and ENDRA Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IRIDEX00203.00
ENDRA Life Sciences0000N/A

IRIDEX currently has a consensus price target of $6.50, suggesting a potential downside of 15.69%. Given IRIDEX's higher possible upside, equities research analysts clearly believe IRIDEX is more favorable than ENDRA Life Sciences.

Institutional & Insider Ownership

32.6% of IRIDEX shares are owned by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are owned by institutional investors. 2.0% of IRIDEX shares are owned by insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares IRIDEX and ENDRA Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IRIDEX-21.54%-38.60%-24.99%
ENDRA Life SciencesN/A-492.76%-288.58%

Summary

IRIDEX beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.


IRIDEX Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$9.08+0.3%$264.61 million$50.23 million-151.33Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.36+11.4%$171.12 million$3.38 million-3.85Decrease in Short Interest
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.88+4.4%$123.35 millionN/A0.00
FONR
FONAR
1.1$18.32+2.9%$120.07 million$85.69 million17.28News Coverage
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.15+2.6%$91.68 millionN/A-1.51Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.18+1.8%$90.69 million$10,000.00-1.18Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.79+1.7%$86.77 million$2.39 million-2.27Decrease in Short Interest
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$16.90+1.3%$39.06 million$1.50 million-0.97Analyst Upgrade
Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.37+0.4%$32.42 million$5.51 million-0.11Analyst Downgrade
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63+5.7%$27.20 million$6.57 million-0.01
STRR
Star Equity
0.1$2.80+5.4%$13.78 million$114.18 million-0.89
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.